Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis

• Egile Nagusiak: Jiaxin Zhu (Egilea), Tiantian Zhang (Egilea), Jiahao Li (Egilea), Junming Lin (Egilea), Wenhua Liang (Egilea), Wenjie Huang (Egilea), Ning Wan (Egilea), Jie Jiang (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2019-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitions are being strongly recommended for the treatment of various cancers, while the efficacy of PD-1/PD-L1 inhibitions varies from individuals. It is urgent to explore some biomarkers to screen the most appro...